RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Shenzhen Chipscreen Biosciences is expected to be one of the first IPOs on Shanghai’s new STAR Board for young technology companies. STAR IPOs are expected to begin next week. Chipscreen specializes in discovering and developing novel small molecule drugs for needs in oncology, metabolic disease and autoimmune disease. Unlike many STAR IPO companies, Chipscreen is profitable. In 2015, its cancer drug, Chidamide, was launched in China to treat NHL T-Cell lymphoma. It is currently being tested for US approval. The company currently has 14 research projects underway.
Source: China Biotoday
